关于非小细胞肺癌的ALK-TKI全球研究趋势:一个文献分析
Yafeng Liu1, Zhaojin Han1, Yujia Li1
1Department of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Frontiers in pharmacology
|September 2, 2025
概括
这项文献计量研究分析了对非小细胞肺癌 (NSCLC) 的无细胞淋巴瘤激酶激酶抑制剂 (ALK-TKIs) 的十年研究. 它强调了关键的趋势,有影响力的研究,以及ALK-TKI治疗NSCLC的未来方向.
科学领域:
- 癌症学
- 药理学
- 图书识别技术
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 在一个显著的NSCLC患者中发生了无细胞淋巴瘤激酶 (ALK) 基因突变.
- 在ALK阳性NSCLC中,ALK氨酸激酶抑制剂 (ALK- TKIs) 具有很高的疗效.
研究的目的:
- 在过去十年 (2015-2024年) 中对NSCLC ALK-TKI研究进行文献分析.
- 确定ALK-TKI治疗NSCLC的趋势,关键贡献者和新兴研究领域.
主要方法:
- 在 Web of Science 核心集合 (2015-2024) 中进行文献搜索.
- 包括英语原创研究和评论文章.
- 从ClinicalTrials.gov收集临床试验数据
- 使用CiteSpace,VOSviewer,Excel和R进行文献分析.
主要成果:
- 在2015年至2024年期间确定了2877份出版物和198项临床试验.
- 中国在出版物方面领先; 马萨诸塞州总医院是最富有成效的机构.
- 主要研究领域包括"洛拉丁尼布"",抗药性"",循环瘤DNA"和"免疫疗法".
结论:
- 本研究提供了过去十年来NSCLCALK-TKI发展的全面概述.
- 个性化和精准医学方法是NSCLC中ALK-TKI治疗的未来方向.
更多相关视频
07:50Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
398
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
8.0K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
